Navigation Links
Milestone Biosciences, LLC Further Strengthens Executive Management Team
Date:8/14/2008

Eric P. Loukas, Industry Veteran, Named as CEO

Frank Jacobucci Co-Founder, Named as President and COO

ALTAMONTE SPRINGS, Fla., Aug. 14 /PRNewswire/ -- Milestone Biosciences, LLC, a privately held specialty biotechnology company focused on in-licensing and commercialization of niche oncology products, today announced the appointment of Eric P. Loukas as Chief Executive Officer, effective August 12, 2008. Current President, CEO and Co-founder, Frank Jacobucci, will become President and Chief Operating Officer and will continue to be heavily involved in the company's development, growth and expansion.

"We are pleased to welcome Mr. Loukas to our team. His leadership skills combined with his strategic and industry insight will provide Milestone with the depth of expertise required as we move forward at an accelerated pace, said Frank Jacobucci, Milestone's President and COO.

"I am excited to join Milestone Biosciences at this important stage of its growth," commented Mr. Loukas. "The company's unique business model will provide the opportunity for cancer patients to have access to a broader range of therapies and I look forward to working with the rest of the team and our partners to realize the full potential of this innovative company."

Mr. Loukas brings to the team over 21 years of industry experience. Prior to joining Milestone, Mr. Loukas was Executive Vice President, Chief Operating Officer, General Counsel and Corporate Secretary of MGI PHARMA, INC., where he was responsible for MGI's commercial, medical affairs, manufacturing, regulatory, quality, government affairs, reimbursement and legal operations. Mr. Loukas joined MGI in July 2004 as Senior Vice President, General Counsel and Corporate Secretary. Prior to joining MGI, he served as Division Counsel at 3M Pharmaceuticals, a division of 3M Company, where he provided legal and strategic counsel to the global management team of a $1 billion pharmaceutical business. Early in Mr. Loukas' career he spent six years, first in research and then pharmaceutical sales, at Bristol Myers, Janssen Pharmaceutical and McNeil Pharmaceutical. He received his B.A. degree in experimental psychology from The State University of New York at Albany, an M.S. degree in pharmacology from Rutgers University and J.D. degree from The John Marshall Law School.

About Milestone

Founded in AltaMonte Springs, Florida in January 2007, Milestone Biosciences, LLC is a privately held specialty biotech company with offices in Florida, Minnesota and New Jersey, that focuses on in-licensing and commercializing niche oncology products that would otherwise have limited exposure in the oncology marketplace. Milestone is dedicated to utilizing its broadly-based commercial expertise in oncology to make these niche oncology products available to patients whose treatment options are limited, or where there are recognized unmet medical needs. Milestone also seeks to partner with smaller R&D-focused companies and other companies with no U.S. commercial presence, to commercialize their niche oncology products and thus enable them to continue doing what they do best.


'/>"/>
SOURCE Milestone Biosciences, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Milestone to Report Results for 2008 Second Quarter on Thursday, August 14, 2008
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
4. Cochlear Announces Milestone in Hearing Restoration With 120,000 Nucleus(R) Cochlear Implants
5. Families Embrace Science/Technology-based Ancestry Tracing Marking Milestone in Black Family Reunion Celebrations Across the Nation
6. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
7. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
8. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
9. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
10. Milestone Scientific to Host 2008 Annual Meeting of Stockholders on Thursday, June 5, 2008 in New York City
11. Oncothyreon to receive milestone payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
Breaking Biology Technology:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):